Jiayi Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jiayi Li has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
- Huy N. Trinh
Pacific Health Foundation
12 shared publications - Mindie H. Nguyen
Division of Gastroenterology and Hepatology Department of Medicine Stanford University Medical Center Palo Alto California USA
12 shared publications - Vincent G. Nguyen
Pacific Health Foundation
6 shared publications An K. Le
5 shared publications- Jian Q. Zhang
Chinese Hospital, San Francisco, CA, USA
5 shared publications Jian Zhang
5 shared publications
Latest Publications
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6) , S-1130-1130
Sa1488 - Adherence to Aasld Treatment Guidelines on Treatment Initiation Among Treatment-Eligible Patients with Chronic Hepatitis B: Experiences from Primary Care and Referral Practices
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6) , S-1130-1130
Sa1488 - Adherence to Aasld Treatment Guidelines on Treatment Initiation Among Treatment-Eligible Patients with Chronic Hepatitis B: Experiences from Primary Care and Referral Practices
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S1083
County and Ethnic-Specific HBV Prevalence and Total Disease Burden in California: Estimates by Disease Status Using Community-Based Real-World Data
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S1083
County and Ethnic-Specific HBV Prevalence and Total Disease Burden in California: Estimates by Disease Status Using Community-Based Real-World Data
- 1 April 2015
- Published by Elsevier in Gastroenterology
- Vol. 148 (4) , S-992-992
729 Poor Adherence and Poor Persistency of Consistent Adherence to AASLD Guidelines for Hepatocellular Carcinoma (HCC) Screening and Surveillance in Chronic Hepatitis B (CHB) Patients at Both University and Community Clinics: A Multicenter U.S. Cohort Study
- 1 April 2015
- Published by Elsevier in Gastroenterology
- Vol. 148 (4) , S-992-992
729 Poor Adherence and Poor Persistency of Consistent Adherence to AASLD Guidelines for Hepatocellular Carcinoma (HCC) Screening and Surveillance in Chronic Hepatitis B (CHB) Patients at Both University and Community Clinics: A Multicenter U.S. Cohort Study
- 25 July 2014
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 59 (9) , 2091-2099
Low Treatment Rates in Patients Meeting Guideline Criteria in Diverse Practice Settings
Data on usage of antiviral therapy and application of chronic hepatitis B (CHB) management guidelines in different settings are limited. Our goal is to evaluate the proportion of treatment-eligible patients by 6-month follow-up and treatment rate among eligible patients by 12-month follow-up in diverse settings. In this retrospective cohort study, 1,976 treatment-naïve CHB patients were categorized as primary care physician (PCP) group if seen by community PCP (n = 329), gastroenterology (GI) group if seen by community gastroenterologists (n = 1,268), and hepatology group if seen by university hepatologists (n = 379). Treatment eligibility was based on the US Panel 2008 and American Association for the Study of Liver Diseases (AASLD) 2009 guidelines. All groups had similar age, gender, and ethnic distribution. GI and hepatology groups had similar treatment eligibility rates by US Panel (53–54 %) and AASLD guidelines (24–25 %). However, treatment rate was significantly higher in hepatology compared to GI group by the US Panel guideline (59 vs. 45 %, P = 0.001). PCP group had the lowest eligibility and treatment rates by both guidelines. Common reasons for non-treatment were perceived “normal” alanine aminotransferase, desire for further observation, and patient refusal. Male gender, age >50, and subspecialty care predicted treatment initiation in treatment-eligible patients. Less than half of treatment-eligible patients at primary care clinics received treatment. Community gastroenterology and university liver clinics treated about one-half to two-thirds of eligible patients. Patient and provider education should highlight treatment benefits and the new alanine aminotransferase upper limit of normal.
- 25 July 2014
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 59 (9) , 2091-2099
Low Treatment Rates in Patients Meeting Guideline Criteria in Diverse Practice Settings
Data on usage of antiviral therapy and application of chronic hepatitis B (CHB) management guidelines in different settings are limited. Our goal is to evaluate the proportion of treatment-eligible patients by 6-month follow-up and treatment rate among eligible patients by 12-month follow-up in diverse settings. In this retrospective cohort study, 1,976 treatment-naïve CHB patients were categorized as primary care physician (PCP) group if seen by community PCP (n = 329), gastroenterology (GI) group if seen by community gastroenterologists (n = 1,268), and hepatology group if seen by university hepatologists (n = 379). Treatment eligibility was based on the US Panel 2008 and American Association for the Study of Liver Diseases (AASLD) 2009 guidelines. All groups had similar age, gender, and ethnic distribution. GI and hepatology groups had similar treatment eligibility rates by US Panel (53–54 %) and AASLD guidelines (24–25 %). However, treatment rate was significantly higher in hepatology compared to GI group by the US Panel guideline (59 vs. 45 %, P = 0.001). PCP group had the lowest eligibility and treatment rates by both guidelines. Common reasons for non-treatment were perceived “normal” alanine aminotransferase, desire for further observation, and patient refusal. Male gender, age >50, and subspecialty care predicted treatment initiation in treatment-eligible patients. Less than half of treatment-eligible patients at primary care clinics received treatment. Community gastroenterology and university liver clinics treated about one-half to two-thirds of eligible patients. Patient and provider education should highlight treatment benefits and the new alanine aminotransferase upper limit of normal.